Health Technology AnGes, Inc. Business Summary
AnGes, Inc. engages in the research and development of gene-based medical products. It offers genetic medicines such as hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, and others. It is also involved in the research and development of medical equipment, which improves blood circulation by regenerating blood vessels and NfkB which controls various inflammations. The company was founded on December 17, 1999 and is headquartered in Ibaraki, Japan.
Financial Highlights
Dec 2019
JPY USD Revenue 326.75M 2.99M Gross Profit 235.16M 2.15M Operating income -3,270.00M -29.99M Income before tax -3,751.60M -34.41M Net income -3,750.82M -34.40M EBITDA -3,262.68M -29.92M Diluted EPS -35.81 -0.32 Dividends Per Share 0 0 Total Assets 12,524.60M 115.24M Total liabilities 469.24M 4.31M Total equity 12,055.35M 110.93M Operating cash flow -2,179.91M -19.99M Currency in JPY Currency in USD
Historical Data Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Revenue
430.15M
514.26M
365.18M
610.05M
326.75M
Gross Profit
217.14M
281.91M
163.69M
418.87M
235.16M
Operating income
-4,171.98M
-4,615.47M
-3,288.68M
-3,065.25M
-3,270.00M
Income before tax
-4,124.15M
-4,760.67M
-3,744.18M
-3,003.00M
-3,751.60M
Net income
-4,143.33M
-4,776.78M
-3,764.69M
-2,996.62M
-3,750.82M
EBITDA
-4,123.00M
-4,548.16M
-3,259.32M
-3,057.39M
-3,262.68M
Diluted EPS
-74.53
-75.29
-49.38
-34.46
-35.81
Dividends Per Share
0
0
0
0
0
Total Assets
4,765.68M
4,539.20M
3,963.60M
8,050.67M
12,524.60M
Total liabilities
544.33M
669.81M
341.72M
316.21M
469.24M
Total equity
4,221.35M
3,869.38M
3,621.88M
7,734.45M
12,055.35M
Operating cash flow
-4,595.74M
-4,983.69M
-2,991.22M
-2,522.50M
-2,179.91M
Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Revenue
3.55M
4.73M
3.25M
5.52M
2.99M
Gross Profit
1.79M
2.59M
1.45M
3.79M
2.15M
Operating income
-34.46M
-42.47M
-29.32M
-27.75M
-29.99M
Income before tax
-34.06M
-43.81M
-33.39M
-27.19M
-34.41M
Net income
-34.22M
-43.96M
-33.57M
-27.13M
-34.40M
EBITDA
-34.05M
-41.85M
-29.06M
-27.68M
-29.92M
Diluted EPS
-0.61
-0.69
-0.44
-0.31
-0.32
Dividends Per Share
0
0
0
0
0
Total Assets
39.61M
38.91M
35.18M
73.37M
115.24M
Total liabilities
4.52M
5.74M
3.03M
2.88M
4.31M
Total equity
35.09M
33.17M
32.15M
70.49M
110.93M
Operating cash flow
-37.96M
-45.86M
-26.67M
-22.83M
-19.99M
Valuation Measures
Dec 2019
PER -- ROA -36.45% ROE -37.90% Operating margin -1,000.73% Profit margin -1,147.88%
Key executives
President & Representative Director:
Ei Yamada
Director, Executive Officer & Manager-Finance:
Tetsuji Yoneo
Director & Manager-Drug Discovery Research:
Kazuo Suzuki
Executive Officer, Manager-R&D Promotion:
Hajime Watanabe
Manager-Accounting:
Jun Sakurai Shareholders
BlackRock Fund Advisors (1.0%)
Shionogi & Co., Ltd. (0.9%)
MORISHITA RYUICHI (0.5%)
JPMorgan Asset Management (UK) Ltd. (0.2%)
BlackRock Advisors (UK) Ltd. (0.1%)
TIAA-CREF Investment Management LLC (0.1%)
SSgA Funds Management, Inc. (0.0%)
Credit Suisse Asset Management (Schweiz) AG (0.0%)
ISHIHARA SANGYO KAISHA LTD. (0.0%)
Siemens Fonds Invest GmbH (0.0%)
Contact Details Website: http://www.anges.co.jp Address:
Saito Bio-Incubator, 1/F,
7-7-15 Saito-Asagi,
Osaka,
567-0085,
Japan
Phone:
+81.72.643.3590
Related Companies
AnGes USA, Inc.
AnGes Euro Ltd.
Competitors
Sienna Biopharmaceuticals, Inc.
Copyright © 2020 FactSet Research Systems Inc. All rights reserved.
Last Updated on 24 Nov, 2020
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close
